BioFocus announced today that its Compound Focus, Inc. subsidiary has signed a three-year compound management services agreement with Lundbeck Research USA, Inc. Under the terms of this agreement, Compound Focus will manage Lundbeck’s liquid chemical library collection, distributing screening sets to high throughput screening centers in both USA and Europe. These services will be provided by Compound Focus’ compound management facility in South San Francisco, USA.

“We are pleased to welcome Lundbeck Research USA, Inc. as a new client,” said Scott Snyder, Compound Focus’ General Manager. “Compound Focus continues to attract commercial, government and charitable organizations that see our state of the art automation and compound management experience as a complement to their discovery operations.”

About Lundbeck Research USA, Inc.

Lundbeck Research USA, Inc. is engaged in drug discovery aimed at treating CNS diseases by designing small molecule therapeutics. Lundbeck Research USA, Inc. mission is to improve the quality of life for those suffering from psychiatric and neurological disorders.

About Compound Focus

Compound Focus, Inc. is a service division of BioFocus and provides a range of compound management services. It is home to sample collections owned by government, academic and commercial organizations and to the National Institutes of Health Molecular Libraries Small Molecule Repository.

About BioFocus

BioFocus aims to expand its partners’ drug pipelines by accelerating the gene-to-drug candidate discovery process. This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry, ADME/PK services, supported by unique chemogenomic and informatics tools, and compound library acquisition, storage and distribution services. As a service division of Galapagos, BioFocus has over 250 employees in three countries worldwide.